The SWI/SNF chromatin remodeling complex is composed of approximately 15 subunits, and approximately 20% of all cancers carry mutations in the genes encoding these subunits. Most of the genetic alterations in these genes are loss-of-function mutations. The identification of vulnerability based on synthetic lethality in cancers with SWI/SNF chromatin remodeling complex deficiency contributes to precision medicine. The SWI/SNF chromatin remodeling complex is involved in transcription, DNA repair, DNA replication, and chromosomal segregation. Cancers with deficiency in the SWI/SNF chromatin remodeling complex show increased vulnerability derived from the loss of these functions. Synthetic lethal targets have been identified based on vulnerabilities in the functions of the SWI/SNF chromatin remodeling complex.
| THER APEUTI C S TR ATEGY BA S ED ON SYNTHE TI C LE THALIT Y FOR LOSS -OF-FUN C TI ON MUTATED C AN CER S
Current precision medicine strategies for human cancers target activated proteins such as the tyrosine kinases EGFR, BRAF, and ALK-fusion; these proteins are activated by gain-of-function genetic aberrations including gene mutation, amplification, and fusion ( Figure 1 ). [1] [2] [3] Activated oncogenes constitute a specific vulnerability of cancer cells. Inhibition of the synthesis or activity of these oncogenes results in cell death, specifically in cells expressing the activated oncogene; the dependence of cells on an oncogene for survival is defined as "oncogene addiction". 4 Only a fraction of cancers have an activated oncogene, whereas many cancers have other genetic aberrations such as loss-of-function (LOF) mutations. Certain LOF gene mutations of tumor suppressor genes confer druggable vulnerabilities on cancer cells. However, because genes with LOF mutations are inactivated, the LOF mutation gene product is not a target for inhibition ( Figure 1 ). Harnessing synthetic lethality, such as that based on LOF gene mutations, has emerged as an attractive therapeutic strategy; however, to date, this strategy has not been widely successful. Synthetic lethality is defined by an interdependent relationship between 2 genes, which means that simultaneous loss of 2 genes, but not loss of either gene alone, leads to cell death ( Figure   1 ). [5] [6] [7] Cancer cells harboring a LOF gene mutation would therefore be vulnerable to inhibition of the synthetic lethal target.
In this review, "synthetic lethal therapy" is defined as cancer therapy based on synthetic lethality. This strategy is based on the assumption that a cancer patient has a LOF mutation of "gene A" and gene A is synthetic lethal with gene B (Figure 2 ). In cancer cells, gene A is the LOF gene, and therapy with an inhibitor of B causes cell death based on synthetic lethality because of the simultaneous suppression of the function of both A and B. In normal cells, gene A is normal; therefore, inhibition of gene B does not affect the survival of normal cells. Synthetic lethal therapy is expected to have high selectivity against cancer cells and few side-effects.
Thus, the identification of cancer vulnerabilities associated with LOF gene mutations should lead to marked improvements in cancer therapy, as epitomized by the success of poly(ADP-ribose) polymerase (PARP)1-targeted therapy against hereditary breast and ovarian cancers harboring LOF mutations of the BRCA1 and BRCA2 genes. 8, 9 
| ROLE OF CHROMATIN REG UL ATING FAC TO R S
Chromatin regulating factors are largely divided into 2 groups: chromatin remodeling complexes and histone modifying factors ( Figure 3 ). Chromatin remodeling complexes use the energy of ATP hydrolysis and maintain chromatin structure by opening or closing chromatin through sliding, ejecting, repositioning, or inserting nucleosomes, which are histone octamers composed of histones H2A, H2B, H3, and H4. 10 Histone modifying factors maintain the 
| G ENE TI C AB NORMALIT Y OF SWI/ S NF CHROMATIN REMODELING G ENE S IN VARI OUS C AN CER S
Recent advances in genome-wide sequencing technologies have contributed to the identification of most gene mutations associated with cancer. Comprehensive genome studies identified mutations in genes involved in chromatin regulation in approximately 50% of cancers. [11] [12] [13] [14] Most of the mutations in chromatin regulating genes are LOF mutations such as deleterious missense mutations, frameshift mutations, and chromosomal deletions. Mutations in SWI/SNF chromatin remodeling genes occur with high frequency in cancer; they are detected in approximately 20% of all cancer patients. 15, 16 The or SSX4) are observed in all synovial sarcoma patients. 19 Most SWI/ SNF chromatin remodeling genes, except the SS18-SSX fusion, cause LOF genetic aberrations in cancer. Therefore, the development of therapies based on synthetic lethality would be a promising therapeutic strategy. In this review, we introduce a synthetic lethal therapy strategy for the treatment of cancers with genetic aberrations of SWI/SNF chromatin remodeling genes (Figures 4 and 5 ).
| SYNTHE TI C LE THAL TARG E TS BA S ED ON TARG E TING THE INTER AC TI ON B E T WEEN 2 SUBUNITS IN THE SWI/S NF CHROMATIN REMODELING COMPLE X
The SWI/SNF chromatin remodeling complex is a large complex composed of many different subunits, including functional subunits, such as catalytic, structural, and DNA binding subunits.
Therefore, cancers deficient in the SWI/SNF chromatin remodeling complex are vulnerable because the interactions between subunits can be targeted for inactivation ( Figure 5A ). SMARCA4 and its paralog SMARCA2 have an ATPase domain that supplies F I G U R E 3 Role of chromatin regulators energy for chromatin remodeling activity. Therefore, the ATPase function of the SWI/SNF chromatin remodeling complex requires either SMARCA4 or SMARCA2. According to the mutually exclusive paralogs SMARCA4 and SMARCA2, the SWI/SNF chromatin remodeling complex exists as a SMARCA4-containing complex or a SMARCA2-containing complex. Therefore, loss of SMARCA4 or SMARCA2 leads to functional deficiency of the SMARCA4containing complex or SMARCA2-containing complex, respectively. Work from our group showed that SMARCA4-deficient lung adenocarcinoma cells are sensitive to siRNA-mediated suppression of SMARCA2. 20 This was supported by follow-up studies. 21, 22 Conversely, SMARCA2-deficient esophageal squamous carcinoma cells are sensitive to inhibition of SMARCA4. 23 These observa- inhibitors because inhibition of BRD2 represses the transcriptional expression of ARID1B. In fact, ARID1A-deficient cancer cells are more sensitive to BRD2 inhibitors than ARID1A-proficient cancer cells. 25 Therefore, BRD2 inhibitors would be promising for the treatment of ARID1A-deficient cancers because of induction of synthetic lethality through suppression of ARID1B.
F I G U R E 4 Genetic abnormality of SWI/SNF chromatin remodeling components in various cancers
SMARCB1 and SS18 are components of the BAF complex.
SMARCB1 is genetically aberrant because of LOF gene mutation or chromosomal deletion in pediatric and juvenile cancers such as rhabdoid tumor and epithelioid sarcoma. 26, 27 SS18 is genetically aberrant because of fusion with SSXs (SSX1, SSX2, or SSX4) in synovial sarcoma. The SS18-SSX fusion protein is incorporated into the BAF complex, resulting in loss of the SMARCB1 protein from the BAF complex. 19, 28 This suggests that the BAF complex containing the SS18-SSX fusion protein is deficient in SMARCB1 function.
SMARCB1-deficient cancer cells and SS18-SSX fusion cancer cells
are synthetic lethal because of inhibition of a subunit of the ncBAF complex, such as BRD9. 18, 29, 30 Thus, BAF complex-deficient cancers, such as SMARCB1-deficient cancers, depend on the function of the residual ncBAF complex. A BRD9 inhibitor would therefore be a promising strategy for SMARCB1-deficient cancers.
Comprehensive analysis of synthetic lethality between 2 factors in all subunits of the SWI/SNF chromatin remodeling complex showed that the SMARCA4-ARID2, SMARCA4-ACTB, and SMARCC1-SMARCC2 pairs are significant for synthetic lethality. 31 Considering synthetic lethality among these pairs, the SMARCA4 and ARID2 relationship would be a potential target for synthetic lethal therapy because SMARCA4 and ARID2 are frequently mutated in cancer.
| SYNTHE TI C LE THAL TARG E TS BA S ED ON TARG E TING THE COMPE TITOR WITH THE SWI/S NF CHROMATIN REMODELING COMPLE X
Transcription is regulated by the balance between the promotion and repression of gene expression by various chromatin regulating factors. Therefore, cancers deficient in the SWI/SNF chromatin remodeling complex are vulnerable because of the abrogation of transcriptional balance ( Figure 5B ). The SWI/SNF chromatin remodeling complex promotes gene expression by inducing chromatin relaxation at the promoter and enhancer regions. In contrast, polycomb repressive complex 2 (PRC2), which is composed of the methyltransferase EZH2 and the noncatalytic regulatory subunits SUZ12 and EED, represses gene expression by promoting chromatin compaction through histone H3 K27 trimethylation (H3K27me3) at the promoter and enhancer regions. The SWI/ SNF chromatin remodeling complex and PRC2 thus interact in a competitive manner to promote and repress transcription. 32, 33 In cancer cells deficient in SMARCA4, SMARCB1, ARID1A, and PBRM1 of the SWI/SNF chromatin remodeling complex, inhibition of EZH2 causes synthetic lethality. 32, [34] [35] [36] The HDAC6 inhibitors would be promising agents for the treatment of ARID1A-deficient cancers.
| SYNTHE TI C LE THAL TARG E TS BA S ED ON TARG E TING THE FUN C TI ON OF THE SWI/S NF CHROMATIN REMODELING COMPLE X
The SWI/SNF chromatin remodeling complex functions in transcription, DNA repair, DNA replication, and chromosomal segregation.
Therefore, cancers deficient in the SWI/SNF chromatin remodeling complex are vulnerable because of the abrogation of these cellular functions ( Figure 5C ). Regarding DNA repair, the SWI/SNF chromatin remodeling complex is involved in DNA double-strand break repair and DNA damage checkpoint regulation. The PARP1 inhibitor olaparib is approved for BRCA1/2-deficient ovarian and breast cancers, which are deficient in homologous recombination repair, a DNA double-strand break repair mechanism. In ARID1A-deficient cancers, which are deficient in homologous recombination-mediated DNA double-strand break repair, treatment with a PARP inhibitor causes synthetic lethality. 41 In the SWI/SNF chromatin remodeling complex, the BAF complex is required for chromatin binding of topoisomerase II (TOP2), which is necessary for DNA replication and chromosomal segregation. ARID1A mediates the physical interaction between the BAF complex and TOP2. 42 [43] [44] [45] [46] [47] The SWI/SNF chromatin remodeling complex is involved in the regulation of several metabolic pathways. The energy supply in cancer cells is derived from ATP generated by the glycolytic pathway. However, SMARCA4-deficient lung cancer cells depend on energy supplied by the oxidative phosphorylation pathway rather than the glycolytic pathway, and are therefore sensitive to inhibition of oxidative phosphorylation. 48 In addition, the cells are exposed to oxidative stress, such as that caused by reactive oxygen species (ROS), which damage DNA and proteins. Excessive generation of ROS leads to induction of cell death. However, the intracellular antioxidant system can effectively mediate resistance to oxidative stress by suppressing ROS through the antioxidant metabolite glutathione (GSH). Thus, the balance between oxidative stress and the antioxidant metabolite GSH maintains cellular homeostasis. We recently showed that impairment of the GSH metabolic pathway is a vulnerability of ARID1A-deficient cancer cells. 49 Glutathione is a tripeptide metabolite synthesized from cysteine, glutamate, and glycine. ARID1A positively regulates the transcription of SLC7A11, which encodes a protein required for the maintenance of intracellular cysteine. 49 55, 56 In addition, ROS could contribute to cancer transformation by promoting gene mutation or by stimulating cellular signaling. [57] [58] [59] [60] The basal level of ROS increases as a result of a decrease of GSH in ARID1A-deficient ovarian cancer cells. 49 These findings suggest that ARID1A abrogation is involved in oncogenesis by contributing to a dysregulated balance between ROS and GSH homeostasis. The clinical success rate of therapy based on biomarkers of LOF mutations in SWI/SNF chromatin remodeling genes could be improved by identifying promising drug targets using the concept of synthetic lethality. Many synthetic lethal targets for cancers with SWI/SNF chromatin remodeling complex deficiency have been identified. Inhibitors of these synthetic lethal targets have been developed, many of which are currently under clinical trials or approved for clinical use (Table 1) . It is expected that these promising drugs will be approved for clinical application in cancers with SWI/SNF chromatin remodeling complex deficiency in the near future.
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